Dry Eye Disease Market to Observe Stupendous Growth by 2034

DelveInsight's analysis indicates a promising outlook for the dry eye disease market from 2024 to 2034, with positive growth anticipated. This growth trajectory is attributed to the emergence of numerous therapies in the pipeline set to launch within the forecast period.

DelveInsight's Dry Eye Disease Market Insightsreport includes a comprehensive understanding of current treatment practices, dry eye disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Key Takeaways from the Dry Eye Disease Market Report

— According to DelveInsight's analysis, the market size for dry eye diseasewas found to be USD 3.7 billion in the 7MM in 2023.

— The United States accounted for the highest market size of DED ~73% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

— In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly 54.6 million in 2023.

— Leading dry eye diseasecompanies such as Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, OKYO Pharma, AxeroVision, Inc., Glaukos Corporation, Oculis, and others are developing novel dry eye disease drugs that can be available in the dry eye disease market in the coming years.

— The promising dry eye disease therapies in the pipeline include PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others.

Discover which therapies are expected to grab the major dry eye diseasemarket share @ Dry Eye Disease Market Report

Dry Eye Disease Overview

Dry eye disease (DED) is a common chronic condition characterized by inadequate tear production or excessive tear evaporation, leading to inflammation and damage to the eye's surface. Causes of DED are multifactorial and include aging, hormonal changes, prolonged screen use, environmental factors (dry climates, wind), certain medications, autoimmune conditions, and contact lens wear. Symptoms often include persistent dryness, redness, irritation, a gritty or sandy sensation, sensitivity to light, blurry vision, and in some cases, paradoxical excessive tearing.

Diagnosing DED typically involves a thorough eye examination by an ophthalmologist or optometrist. Common diagnostic tests include the Schirmer test, tear breakup time, and ocular surface staining with dyes such as fluorescein or lissamine green to detect surface damage. Early diagnosis and management are essential to prevent complications like corneal damage and vision impairment.

Dry Eye Disease Epidemiology Segmentation

The dry eye disease epidemiology section provides insights into the historical and current dry eye disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The dry eye disease market reportproffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

— Total Diagnosed Prevalent Cases

— Gender-specific Diagnosed Prevalent Cases

— Age-specific Diagnosed Prevalent Cases

— Severity-specific Diagnosed Prevalent Cases

Dry Eye Disease Treatment Market

Pharmacological treatments play a pivotal role in the comprehensive management of dry eye disease. Common solutions like artificial tears provide quick relief by enhancing the tear film, while prescription medications such as cyclosporine (e.g., RESTASIS) and lifitegrast (e.g., XIIDRA) help alleviate symptoms through their anti-inflammatory effects. Recently approved therapies, including VEVYE (cyclosporine ophthalmic solution)/CyclASol and MIEBO (NOV03), offer new and promising options.

Beyond pharmacological approaches, other strategies for managing DED include in-office treatments like intense pulsed light therapy and meibomian gland expression, as well as eyelid care techniques such as warm compresses and lid scrubs. For more severe cases, lifestyle changes, punctal plugs, or scleral contact lenses may be considered to provide additional symptom relief.

The eye drop market is largely focused on alleviating dry eye symptoms using moisturizing agents such as hyaluronic acid. However, there is a notable gap in effective treatments for viral keratoconjunctivitis, a condition often mismanaged with antibiotics. Marinomed Biotech AG's MAM-1001-3 eye drops aim to address this need by leveraging Carragelose, a red seaweed-derived polymer with exceptional moisturizing and broad-spectrum antiviral properties.

Classified as a medical device and in the pre-launch phase with MDD certification, MAM-1001-3 provides dual benefits: soothing dry, irritated eyes and potentially offering a targeted solution for viral keratoconjunctivitis, thereby advancing patient care in ocular health. In summary, implementing a personalized combination of these management strategies can effectively reduce symptoms and enhance the quality of life for individuals with DED.

To know more about dry eye disease treatment guidelines, visit @ Dry Eye Disease Management

Dry Eye Disease Pipeline Therapies and Key Companies

— PL9643: Palatin Technologies, Inc.

— Reproxalap: Aldeyra Therapeutics, Inc.

— RGN-259 (Tß4): ReGenTree/RegeneRx Biopharmaceuticals, Inc.

— Tavilermide (MIM-D3): Mimetogen

— AR-15512: Alcon/Aerie Pharmaceuticals

— BRM421: BRIM Biotechnology, Inc.

— SI-614: Seikagaku Corporation

— SkQ1 eye drops: Mitotech

— SJP-0132: Senju Pharmaceutical

— Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar

— ST-100 (Vezocolmitide): Stuart Therapeutics

— VVN001: VivaVision Biotech

— Tanfanercept Ophthalmic Solution/HL036: HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd.

— RP101: Redwood Pharma AB

— AXR-270 (cream): AxeroVision, Inc.

— OK-101: OKYO Pharma

— AXR-270: AxeroVision, Inc.

— AXR-159: AxeroVision, Inc.

— GLK-301 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation

— Licaminlimab (OCS-02): Oculis

Discover more about dry eye disease drugsin development @ Dry Eye Disease Clinical Trials

Dry Eye Disease Market Dynamics

The dry eye disease market dynamics are expected to change in the coming years. Dry eye is a highly prevalent condition, especially among the aging population, creating a substantial need for effective diagnosis, treatment, and management solutions. Current treatment options, such as artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs, enable tailored approaches to address the condition. Increased public education campaigns can raise awareness and encourage individuals to seek help, while collaboration among pharmaceutical companies, research institutions, and healthcare providers can drive the development of novel therapies and diagnostic tools for dry eye disease.

Furthermore, potential therapies are being investigated for the treatment of dry eye disease, and it is safe to predict that the treatment space will significantly impact the dry eye diseasemarket during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the dry eye diseasemarket in the 7MM.

However, several factors may impede the growth of the dry eye disease market. Some dry eye treatments, particularly prescription medications, can cause side effects like blurred vision or itching, while the cost of treatment, including medications and frequent healthcare visits, can be burdensome for patients; additionally, intense market competition increases pricing pressures and marketing expenditures for companies, and failure to properly diagnose or treat dry eye may lead to disease progression and complications, significantly impacting patient health and well-being.

Moreover, dry eye diseasetreatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, dry eye disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact dry eye diseasemarket growth.

Dry Eye Disease Market Report Metrics DetailsStudy Period 2020-2034Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].Dry Eye Disease Market Size in 2023 USD 3.7 BillionKey Dry Eye Disease Companies Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, OKYO Pharma, AxeroVision, Inc., Glaukos Corporation, Oculis, and othersKey Pipeline Dry Eye Disease Therapies PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others

Scope of the Dry Eye DiseaseMarket Report

— Therapeutic Assessment: Dry Eye Diseasecurrent marketed and emerging therapies

— Dry Eye DiseaseMarket Dynamics:Key Market Forecast Assumptions of Emerging Dry Eye Disease Drugs and Market Outlook

— Competitive Intelligence Analysis:SWOT analysis and Market entry strategies

— Unmet Needs, KOL's views, Analyst's views, Dry Eye Disease Market Access and Reimbursement

Download the report to understand which factors are driving dry eye disease market trends@Dry Eye Disease Market Trends

Table of Contents

1 Key Insights2 Report Introduction3 Dry Eye Disease (DED) Market Overview at a Glance3.1 Market Share (%) Distribution by Therapies of DED in 20203.2 Market Share (%) Distribution by Therapies of DED in 20344 Epidemiology and Market Methodology of DED5 Executive Summary of Dry Eye Disease (DED)6 Key Events7 Disease Background and Overview7.1 Introduction7.2 Tear Film Working7.3 Etiology7.4 Risk Factors7.5 Pathophysiology7.6 Symptoms and Clinical Presentations7.7 Diagnosis7.7.1 Diagnostic Criteria7.7.1.1 Comparison of Dry Eye Definition and Diagnostic Criteria between JDES/ADES and DEWS II7.7.1.2 Diagnostic Criteria of the JDES, 1995 Version7.7.1.3 Diagnostic criteria of DED proposed by the JDES (2006 version)7.7.2 Differential Diagnosis7.7.3 Diagnostic Algorithm7.7.4 Diagnostic Scheme7.7.5 Diagnostic Guidelines7.7.5.1 Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology7.8 Treatment and Management7.8.1 Treatment Algorithm7.8.2 Treatment Guidelines7.8.2.1 TFOS DEWS II Management and Therapy Guidelines7.8.2.2 Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology8 Epidemiology and Patient Population8.1 Key Findings8.2 Assumptions and Rationale: The 7MM8.2.1 Diagnosed Prevalence of DED8.2.2 Gender-specific Prevalence of DED8.2.3 Age-specific Diagnosed Prevalence of DED8.2.4 Severity-specific Diagnosed Prevalence of DED8.3 Total Diagnosed Prevalent Cases of DED in the 7MM8.4 The United States8.4.1 Total Diagnosed Prevalent Cases of DED8.4.2 Gender-specific Diagnosed Prevalent Cases of DED8.4.3 Age-specific Diagnosed Prevalent Cases of DED8.4.4 Severity-specific Diagnosed Prevalent Cases of DED8.5 EU4 and the UK8.5.1 Germany8.5.1.1 Total Diagnosed Prevalent Cases of DED in Germany in Germany8.5.1.2 Gender-specific Diagnosed Prevalent Cases of DED in Germany8.5.1.3 Age-specific Diagnosed Prevalent Cases of DED in Germany8.5.1.4 Severity-specific Diagnosed Prevalent Cases of DED in Germany8.5.2 France8.5.2.1 Total Diagnosed Prevalent Cases of DED in France8.5.2.2 Gender-specific Diagnosed Prevalent Cases of DED in France8.5.2.3 Age-specific Diagnosed Prevalent Cases of DED in France8.5.2.4 Severity-specific Diagnosed Prevalent Cases of DED in France8.5.3 Italy8.5.3.1 Total Diagnosed Prevalent Cases of DED in Italy8.5.3.2 Gender-specific Diagnosed Prevalent Cases of DED in Italy8.5.3.3 Age-specific Diagnosed Prevalent Cases of DED in Italy8.5.3.4 Severity-specific Diagnosed Prevalent Cases of DED in Italy8.5.4 Spain8.5.4.1 Total Diagnosed Prevalent Cases of DED in Spain8.5.4.2 Gender-specific Diagnosed Prevalent Cases of DED in Spain8.5.4.3 Age-specific Diagnosed Prevalent Cases of DED in Spain8.5.4.4 Severity-specific Diagnosed Prevalent Cases of DED in Spain8.5.5 The United Kingdom8.5.5.1 Total Diagnosed Prevalent Cases of DED in the UK8.5.5.2 Gender-specific Diagnosed Prevalent Cases of DED in the UK8.5.5.3 Age-specific Diagnosed Prevalent Cases of DED in the UK8.5.5.4 Severity-specific Diagnosed Prevalent Cases of DED in the UK8.6 Japan8.6.1 Total Diagnosed Prevalent Cases of DED8.6.2 Gender-specific Diagnosed Prevalent Cases of DED8.6.3 Age-specific Diagnosed Prevalent Cases of DED in the US8.6.4 Severity-specific Diagnosed Prevalent Cases of DED9 Patient Journey10 Marketed Therapies10.1 Key Cross Competition of Marketed Therapies10.2 CEQUA (cyclosporine ophthalmic solution) 0.09%: Sun Pharm10.2.1 Product Description10.2.2 Regulatory Approval10.2.3 Other Developmental Activities10.2.4 Clinical Development10.2.5 Clinical Trials Information10.2.6 Safety and Efficacy10.2.7 Product Profile10.3 TYRVAYA (varenicline solution): OYSTER POINT PHARMA10.3.1 Product Description10.3.2 Regulatory Approval10.3.3 Other Developmental Activities10.3.4 Clinical Development10.3.5 Clinical Trials Information10.3.6 Safety and Efficacy10.3.7 Product Profile10.4 EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%: ALCON LABS INC/Kala Pharmaceuticals10.4.1 Product Description10.4.2 Regulatory Approvals10.4.3 Other Developmental Activities10.4.4 Clinical Development10.4.5 Clinical Trials Information10.4.6 Safety and Efficacy10.4.7 Product Profile10.5 VEVYE (cyclosporine ophthalmic solution)/ CyclASol: Novaliq/ Harrow Eye10.5.1 Product Description10.5.2 Regulatory Approvals10.5.3 Other Developmental Activities10.5.4 Clinical Development10.5.5 Clinical Trials Information10.5.6 Safety and Efficacy10.5.7 Product Profile10.6 MIEBO (NOV03): Bausch & Lomb Incorporated/Novaliq10.6.1 Product Description10.6.2 Regulatory Approval10.6.3 Other Developmental Activities10.6.4 Clinical Development10.6.5 Clinical Trials Information10.6.6 Safety and Efficacy10.6.7 Product Profile11 Emerging Therapies11.1 Key Cross Competition of Emerging Therapies11.2 PL9643: Palatin Technologies, Inc.11.2.1 Product Description11.2.2 Other Developmental Activities11.2.3 Clinical Development11.2.4 Clinical Trials Information11.2.5 Safety and Efficacy11.2.6 Product Profile11.2.7 Analyst View11.3 Reproxalap: Aldeyra Therapeutics, Inc.11.3.1 Product Description11.3.2 Other Developmental Activities11.3.3 Clinical Development11.3.4 Clinical Trials Information11.3.5 Safety and Efficacy11.3.6 Product Profile11.3.7 Analyst Views11.4 RGN-259 (TB4): ReGenTree/RegeneRx Biopharmaceuticals, Inc.11.4.1 Product Description11.4.2 Other Developmental Activities11.4.3 Clinical Development11.4.4 Clinical Trials Information11.4.5 Safety and Efficacy11.4.6 Product Profile11.4.7 Analyst Views11.5 Tavilermide (MIM-D3): Mimetogen11.5.1 Product Description11.5.2 Other Developmental Activities11.5.3 Clinical Development11.5.4 Clinical Trials Information11.5.5 Safety and Efficacy11.5.6 Product Profile11.5.7 Analyst Views11.6 AR-15512: Alcon/Aerie Pharmaceuticals11.6.1 Product Profile11.6.2 Other Developmental Activities11.6.3 Clinical Development11.6.4 Clinical Trials Information11.6.5 Safety and Efficacy11.6.6 Product Profile11.6.7 Analyst Views11.7 BRM421: BRIM Biotechnology, Inc.11.7.1 Product Description11.7.2 Other Developmental Activities11.7.3 Clinical Development11.7.4 Clinical Trials Information11.7.5 Safety and Efficacy11.7.6 Product Profile11.7.7 Analyst Views11.8 SI-614: Seikagaku Corporation11.8.1 Product Description11.8.2 Other Developmental Activities11.8.3 Clinical Development11.8.4 Clinical Trials Information11.8.5 Product Profile11.8.6 Analyst Views11.9 SkQ1 eye drops: Mitotech11.9.1 Product Description11.9.2 Other Developmental Activities11.9.3 Clinical Development11.9.4 Clinical Trials Information11.9.5 Safety and Efficacy11.9.6 Product Profile11.9.7 Analysts' Views11.10 SJP-0132: Senju Pharmaceutical11.10.1 Product Description11.10.2 Other Developmental Activities11.10.3 Clinical Development11.10.4 Clinical Trials Information11.10.5 Safety and Efficacy11.10.6 Product Profile11.10.7 Analysts' Views11.11 Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar11.11.1 Product Description11.11.2 Other Developmental Activities11.11.3 Clinical Development11.11.4 Clinical Trials Information11.11.5 Safety and Efficacy11.11.6 Product Profile11.11.7 Analysts' Views11.12 ST-100 (Vezocolmitide): Stuart Therapeutics11.12.1 Product Description11.12.2 Other Developmental Activities11.12.3 Clinical Development11.12.4 Clinical Trials Information11.12.5 Safety and Efficacy11.12.6 Product Profile11.12.7 Analysts' Views11.13 VVN001: VivaVision Biotech11.13.1 Product Description11.13.2 Other Developmental Activities11.13.3 Clinical Development11.13.4 Clinical Trials Information11.13.5 Safety and Efficacy11.13.6 Product Profile11.13.7 Analysts' Views11.14 Tanfanercept Ophthalmic Solution/HL036: HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd.11.14.1 Product Description11.14.2 Other Developmental Activities11.14.3 Clinical Development11.14.4 Clinical Trials Information11.14.5 Safety and Efficacy11.14.6 Product Profile11.14.7 Analysts' Views11.15 RP101: Redwood Pharma AB11.15.1 Product Description11.15.2 Other Developmental Activities11.15.3 Clinical Development11.15.4 Clinical Trials Information11.15.5 Safety and Efficacy11.15.6 Product Profile11.15.7 Analysts' Views11.16 AXR-270 (cream): AxeroVision, Inc.11.16.1 Product Description11.16.2 Clinical Development11.16.3 Clinical Trials Information11.16.4 Safety and Efficacy11.16.5 Product Profile11.16.6 Analyst Views11.17 OK-101: OKYO Pharma11.17.1 Product Description11.17.2 Other Developmental Activities11.17.3 Clinical Development11.17.4 Clinical Trials Information11.17.5 Safety and Efficacy11.17.6 Product Profile11.17.7 Analyst Views11.18 AXR-270: AxeroVision, Inc.11.18.1 Product Description11.18.2 Other Developmental Activities11.18.3 Clinical Development11.18.4 Clinical Trials Information11.18.5 Safety and Efficacy11.18.6 Product Profile11.18.7 Analyst Views11.19 AXR-159: AxeroVision, Inc.11.19.1 Product Description11.19.2 Other Developmental Activities11.19.3 Clinical Development11.19.4 Clinical Trials Information11.19.5 Safety and Efficacy11.19.6 Product Profile11.19.7 Analyst Views11.20 GLK-301 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation11.20.1 Product Description11.20.2 Other Developmental Activities11.20.3 Clinical Development11.20.4 Clinical Trials Information11.20.5 Safety and Efficacy11.20.6 Product Profile11.20.7 Analyst Views11.21 Licaminlimab (OCS-02): Oculis11.21.1 Product Description11.21.2 Other Developmental Activities11.21.3 Clinical Development11.21.4 Clinical Trials Information11.21.5 Safety and Efficacy11.21.6 Product Profile11.21.7 Analyst Views12 DED: Market Analysis12.1 Key Findings12.2 Key Market Forecast Assumptions12.3 Market Outlook12.4 Conjoint Analysis12.5 Total Market Size of DED in the 7MM12.6 Market Size of DED by Therapies in the 7MM12.7 Market Size of DED in the United States12.7.1 Total Market Size of DED in the United States12.7.2 Market Size of DED by Therapies12.8 Market Size of DED in EU4 and the UK12.8.1 Germany12.8.1.1 Total Market Size of DED12.8.1.2 Market Size of DED by Therapies12.8.2 France12.8.2.1 Total Market Size of DED12.8.2.2 Market Size of DED by Therapies12.8.3 Italy12.8.3.1 Total Market Size of DED12.8.3.2 Market Size of DED by Therapies12.8.4 Spain12.8.4.1 Total Market Size of DED12.8.4.2 Market Size of DED by Therapies12.8.5 The United Kingdom12.8.5.1 Total Market Size of DED12.8.5.2 Market Size of DED by Therapies12.9 Market Size of DED in Japan12.9.1 Total Market Size of DED12.9.2 Market Size of DED by Therapies in Japan13 Key Opinion Leaders' Views14 SWOT Analysis15 Unmet Needs16 Market Access and Reimbursement16.1 The United States16.1.1 Center for Medicare and Medicaid Services (CMS)16.2 In EU4 and the UK16.2.1 Germany16.2.2 France16.2.3 Italy16.2.4 Spain16.2.5 The United Kingdom16.3 Japan16.3.1 MHLW17 Appendix17.1 Bibliography17.2 Acronyms and Abbreviations17.3 Report Methodology18 DelveInsight Capabilities19 Disclaimer

Related Reports

Dry Eye Disease Epidemiology Forecast

Dry Eye Disease Epidemiology Forecast – 2034report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the dry eye diseaseepidemiology trends.

Dry Eye Disease Pipeline

Dry Eye Disease Pipeline Insight – 2024report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keydry eye diseasecompanies, including Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, among others.

GlaucomaMarket

GlaucomaMarket Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucomacompanies, including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.

Glaucoma Pipeline

Glaucoma Pipeline Insight – 2024report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keyglaucomacompanies, including Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision, HK inno.N, Avirmax Inc., among others.

AboutDelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.

Shruti Thakur info@delveinsight.com +14699457679www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

https://c212.net/c/img/favicon.png?sn=IO05888&sd=2025-01-28

View original content:https://www.prnewswire.com/news-releases/dry-eye-disease-market-to-observe-stupendous-growth-by-2034–delveinsight-302361475.html

SOURCE DelveInsight Business Research, LLP

https://rt.newswire.ca/rt.gif?NewsItemId=IO05888&Transmission_Id=202501281731PR_NEWS_USPR_____IO05888&DateId=20250128